Ten Capital Wealth Advisors LLC Has $370,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Aug 10th, 2023

Ten Capital Wealth Advisors LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 23.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,389 shares of the company’s stock after buying an additional 450 shares during the period. Ten Capital Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $370,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of JNJ. Nisa Investment Advisors LLC raised its holdings in shares of Johnson & Johnson by 0.9% in the first quarter. Nisa Investment Advisors LLC now owns 748,842 shares of the company’s stock valued at $116,071,000 after purchasing an additional 6,836 shares during the last quarter. Scotia Capital Inc. raised its holdings in shares of Johnson & Johnson by 1.6% in the fourth quarter. Scotia Capital Inc. now owns 1,105,147 shares of the company’s stock valued at $195,247,000 after purchasing an additional 17,440 shares during the last quarter. Wisconsin Capital Management LLC increased its holdings in Johnson & Johnson by 0.8% during the first quarter. Wisconsin Capital Management LLC now owns 15,723 shares of the company’s stock worth $2,437,000 after buying an additional 127 shares during the last quarter. Boyar Asset Management Inc. increased its holdings in Johnson & Johnson by 1.1% during the first quarter. Boyar Asset Management Inc. now owns 19,191 shares of the company’s stock worth $2,975,000 after buying an additional 201 shares during the last quarter. Finally, Van Hulzen Asset Management LLC increased its holdings in Johnson & Johnson by 31.8% during the first quarter. Van Hulzen Asset Management LLC now owns 161,743 shares of the company’s stock worth $25,052,000 after buying an additional 39,032 shares during the last quarter. Institutional investors and hedge funds own 67.57% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on JNJ shares. Raymond James raised their price objective on shares of Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a report on Monday, July 24th. Citigroup began coverage on shares of Johnson & Johnson in a research report on Tuesday, May 30th. They set a “buy” rating and a $185.00 target price for the company. TheStreet lowered shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, May 19th. StockNews.com began coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They set a “strong-buy” rating for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, July 31st. Eight analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $171.80.

Check Out Our Latest Analysis on Johnson & Johnson

Insider Activity

In other news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The disclosure for this sale can be found here. Insiders sold a total of 47,163 shares of company stock worth $7,928,856 in the last quarter. 0.20% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $173.07 on Thursday. The firm has a fifty day simple moving average of $164.21 and a two-hundred day simple moving average of $161.13. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $181.04. The company has a market capitalization of $449.80 billion, a PE ratio of 35.03, a P/E/G ratio of 2.90 and a beta of 0.54. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The business had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. During the same period last year, the company earned $2.59 EPS. Johnson & Johnson’s revenue for the quarter was up 6.3% compared to the same quarter last year. Research analysts expect that Johnson & Johnson will post 10.75 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be paid a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s payout ratio is presently 96.36%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.